摘要
In a recent issue of Immunity,Xiao et al.reported that cholesterol 25-hydroxylase(CH25H)is a novel immunometabolic checkpoint and a potential drug target for tumor immunotherapy[1].Their study elucidated how CH25H influences macrophage polarization and reshapes the tumor microenvironment(TME)by regulating the lysosomal 25-hydroxycholesterol(25HC)content and AMPKa activation(Fig.1).Fehleisen and Busch,two physicians from Germany,independently observed significant tumor regression following erysipelas infection in the late 19th century,and they provided the earliest scientific evidence for tumor immunotherapy[2].To date,immunotherapy has emerged as a focal point in cancer treatment,with the concept of the TME pivotal for understanding cancer initiation and progression[3].
基金
National Natural Science Foundation of China(Project:32371243,32171168,32350610248).